Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
272
-
Total 13F shares, excl. options
-
65M
-
Shares change
-
+1.74M
-
Total reported value, excl. options
-
$3.14B
-
Value change
-
+$117M
-
Put/Call ratio
-
0.56
-
Number of buys
-
153
-
Number of sells
-
-123
-
Price
-
$48.36
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2025
325 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q1 2025.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 272 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65M shares
.
Largest 10 shareholders include BlackRock, Inc. (9.74M shares), FARALLON CAPITAL MANAGEMENT LLC (6.11M shares), RTW INVESTMENTS, LP (5.72M shares), VANGUARD GROUP INC (4.28M shares), Deep Track Capital, LP (3M shares), STATE STREET CORP (2.71M shares), BVF INC/IL (2.58M shares), JOHNSON & JOHNSON (2.45M shares), GEODE CAPITAL MANAGEMENT, LLC (1.42M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.32M shares).
This table shows the top 272 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.